Concepedia

Computed Tomography Texture Analysis of Response to Second-Line Nivolumab in Metastatic Non-Small Cell Lung Cancer

Rahul Ladwa, Kate Roberts, Connor O’Leary, Nicole Maggacis, Kenneth J. O’Byrne, Kenneth A. Miles

Lung Cancer Management · 2020 · 13 citations · 13 references

DOIFull text

Open access

Abstract

Patients who derive a clinical benefit to Nivolumab show a computed tomography texture of a hyperdense yet homogenous tumor.

References

13

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 9.8K citations · Full text

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Paul Baas et al. · New England Journal of Medicine · 2015 · 8.4K citations · Full text

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang et al. · Clinical Cancer Research · 2016 · 971 citations

Translational Implications of Tumor Heterogeneity

Clinical Cancer Research · 2015 · 516 citations · Full text